Keywords
Menopausa
Hipogonadismo Masculino
Transição de Gênero
Personalização Terapêutica
How to Cite
Abstract
Hormone Replacement Therapy (HRT) has been a vital tool in medicine for several decades, offering therapeutic solutions for a variety of conditions, from addressing menopausal challenges to male hypogonadism and gender transition support. This review provides a comprehensive analysis of the indications, risks, and benefits of HRT in different patient groups. While the benefits of HRT, such as relief from menopausal symptoms and improved quality of life in certain clinical contexts, are undeniable, there are associated risks that require careful consideration. The risk-benefit relationship varies among individuals, with some populations experiencing significant side effects while others predominantly enjoy therapeutic benefits. Furthermore, individual response to HRT can be influenced by genetic, metabolic, and environmental factors, emphasizing the need for a personalized approach in prescription and monitoring. Socioeconomic issues related to access and the cost of HRT are also crucial, with the need to ensure equity in care. Future research should focus on enhancing our understanding of the risks and benefits for different populations, as well as exploring new formulations and treatment approaches. In summary, HRT offers potential transformative benefits but must be administered with discernment and individualized care.
References
BHASIN, S., et al. (2010). TESTOSTERONE THERAPY IN MEN WITH ANDROGEN DEFICIENCY SYNDROMES: AN ENDOCRINE SOCIETY CLINICAL PRACTICE GUIDELINE. Journal of Clinical Endocrinology & Metabolism.
BURGER, H. G. (2002). HORMONE REPLACEMENT THERAPY IN THE POST-WOMEN'S HEALTH INITIATIVE ERA. REPORT OF A MEETING HELD IN FUNCHAL, MADEIRA, FEBRUARY 24–28, 2002. Climacteric, 5(sup1), 11-36.
COLLINS, P., et al. (2011). TREATMENT OF VASOMOTOR SYMPTOMS IN POST-MENOPAUSAL WOMEN. Maturitas.
CORONA, G., et al. (2016). TESTOSTERONE REPLACEMENT THERAPY AND CARDIOVASCULAR RISK: A REVIEW. The World Journal of Men's Health.
DOHLE, G. R., et al. (2015). GUIDELINES ON MALE HYPOGONADISM. European Association of Urology.
FENELEY, M. R., & CARRUTHERS, M. (2012). IS TESTOSTERONE TREATMENT GOOD FOR THE PROSTATE? STUDY OF SAFETY DURING LONG-TERM TREATMENT. The Journal of Sexual Medicine.
GOOREN, L., et al. (2008). CARE OF TRANSSEXUAL PERSONS. New England Journal of Medicine.
GOOREN, L. J., GILTAY, E. J., & BUNCK, M. C. (2008). LONG-TERM TREATMENT OF TRANSSEXUALS WITH CROSS-SEX HORMONES: EXTENSIVE PERSONAL EXPERIENCE. The Journal of Clinical Endocrinology & Metabolism.
GRANT, J. M., MOTTET, L. A., & TANIS, J. (2011). NATIONAL TRANSGENDER DISCRIMINATION SURVEY REPORT ON HEALTH AND HEALTH CARE. National LGBTQ Task Force.
GRADY, D., et al. (2002). CARDIOVASCULAR DISEASE OUTCOMES DURING 6.8 YEARS OF HORMONE THERAPY: HEART AND ESTROGEN/PROGESTIN REPLACEMENT STUDY FOLLOW-UP (HERS II). JAMA.
HEMBREE, W. C., et al. (2017). ENDOCRINE TREATMENT OF GENDER-DYSPHORIC/GENDER-INCONGRUENT PERSONS. Journal of Clinical Endocrinology & Metabolism.
HERRINGTON, D. M., et al. (2002). COMMON ESTROGEN RECEPTOR POLYMORPHISM AUGMENTS EFFECTS OF HORMONE REPLACEMENT THERAPY ON E-SELECTIN BUT NOT C-REACTIVE PROTEIN. Circulation.
LANGER, R. D. (2017). THE EVIDENCE BASE FOR HRT: WHAT CAN WE BELIEVE? Climacteric, 20(2), 91-96.
LOBO, R. A., et al. (2016). HORMONE-REPLACEMENT THERAPY: CURRENT THINKING. Nature Reviews Endocrinology.
MANSON, J. E., et al. (2013). MENOPAUSAL HORMONE THERAPY AND HEALTH OUTCOMES DURING THE INTERVENTION AND EXTENDED POSTSTOPPING PHASES OF THE WOMEN'S HEALTH INITIATIVE RANDOMIZED TRIALS. JAMA.
MORGENTALER, A., et al. (2015). TESTOSTERONE THERAPY AND CARDIOVASCULAR RISK: ADVANCES AND CONTROVERSIES. Mayo Clinic Proceedings.
MORGENTALER, A., et al. (2016). FUNDAMENTAL CONCEPTS REGARDING TESTOSTERONE DEFICIENCY AND TREATMENT. Mayo Clinic Proceedings.
NORTH AMERICAN MENOPAUSE SOCIETY. (2017). THE 2017 HORMONE THERAPY POSITION STATEMENT OF THE NORTH AMERICAN MENOPAUSE SOCIETY. Menopause.
REISNER, S. L., et al. (2016). GLOBAL HEALTH BURDEN AND NEEDS OF TRANSGENDER POPULATIONS: A REVIEW. The Lancet.
ROSSOUW, J. E., et al. (2002). RISKS AND BENEFITS OF ESTROGEN PLUS PROGESTIN IN HEALTHY POSTMENOPAUSAL WOMEN. JAMA.
ROSSOUW, J. E., et al. (2002). RISKS AND BENEFITS OF ESTROGEN PLUS PROGESTIN IN HEALTHY POSTMENOPAUSAL WOMEN: PRINCIPAL RESULTS FROM THE WOMEN'S HEALTH INITIATIVE RANDOMIZED CONTROLLED TRIAL. JAMA.
SNYDER, P. J., et al. (2016). EFFECTS OF TESTOSTERONE TREATMENT IN OLDER MEN. The New England Journal of Medicine.
TRAISH, A. M., et al. (2011). TESTOSTERONE DEFICIENCY. The American Journal of Medicine.
VIGEN, R., et al. (2013). ASSOCIATION OF TESTOSTERONE THERAPY WITH MORTALITY, MYOCARDIAL INFARCTION, AND STROKE IN MEN WITH LOW TESTOSTERONE LEVELS. JAMA.
WANG, C., et al. (2009). INVESTIGATION, TREATMENT, AND MONITORING OF LATE-ONSET HYPOGONADISM IN MALES. The Journal of Clinical Endocrinology & Metabolism.
WYLIE, K., et al. (2016). SERVING TRANSGENDER PEOPLE: CLINICAL CARE CONSIDERATIONS AND SERVICE DELIVERY MODELS IN TRANSGENDER HEALTH. The Lancet.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Troy Richard Carneiro Filho, Mariana Lisboa de Jesus, Victor Silame Braga, Thiago Leite Siqueira, Ana Luiza de Alencar Amaral